Seres Therapeutics, Inc. Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One
Seres Therapeutics, Inc. (MCRB) had Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One of $18.32 million as of 2022-12-31, per its 10-K filed 2023-03-07.
Discontinued › Notes › Investments › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost · last filed 2023-03-07
- 2022-12-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $18.32M.
- 2022-09-30: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $27.72M.
- 2022-06-30: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $69.23M.
- 2022-03-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $95.02M.
| Period end | Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2022-12-31 | $18.32M 10-K · filed 2023-03-07 |
| 2022-09-30 | $27.72M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $69.23M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $95.02M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $110.76M 10-K · filed 2023-03-07 |
| 2021-09-30 | $119.92M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $140.54M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $176.21M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $137.59M 10-K · filed 2022-03-01 |
| 2020-09-30 | $90.59M 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |